Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B

Thomas Scior¹
José Antonio Guevara-García²
FJ Melendez²
Hassan H Abdallah³
Quoc-Tuan Do⁴
Philippe Bernard⁴

¹Facultad de Ciencias Químicas, Universidad Autónoma de Puebla, Pue, Puebla, Mexico; ²Faculty of Basic Sciences, Technology and Engineering, Laboratory of Research in Bioinorganic and Bioremediation, Universidad Autónoma de Tlaxcala, Apizaco, Tlaxcala, Mexico; ³School of Chemical Sciences, Universiti Sains Malaysia, Penang, Malaysia; ⁴GreenPharma S.A., 3 Allée du Titane, Orléans, France

Abstract: Prior to its total synthesis, a new vanadium coordination compound, called TSAG0101, was computationally designed to inhibit the enzyme protein tyrosine phosphatase 1B (PTP1B). The PTP1B acts as a negative regulator of insulin signaling by blocking the active site where phosphate hydrolysis of the insulin receptor takes place. TSAG001, [V(OH)(picolinamide)], was characterized by infrared (IR) and nuclear magnetic resonance (NMR) spectroscopy; IR: ν/cm⁻¹ 3,570 (NH), 1,627 (C=O, coordinated), 1,417 (C–N), 970/842 (O=V=O), 727 δ (pyridine ring); ¹³C NMR: 5 bands between 122 and 151 ppm and carbonyl C shifted to 180 ppm; and ¹H NMR: 4 broad bands from 7.6 to 8.2 ppm and NH₂ shifted to 8.8 ppm. In aqueous solution, in presence or absence of sodium citrate as a biologically relevant and ubiquitous chelator, TSAG0101 undergoes neither ligand exchange nor reduction of its central vanadium atom during 24 hours. TSAG0101 shows blood glucose lowering effects in rats but it produced no alteration of basal- or glucose-induced insulin secretion on β cells during in vitro tests, all of which excludes a direct mechanism evidencing the extrapancreatic nature of its activity. The lethal dose (LD₅₀) of TSAG0101 was determined in Wistar mice yielding a value of 412 mg/kg. This value is one of the highest among vanadium compounds and classifies it as a mild toxicity agent when compared with literature data. Due to its nonsubstituted, small-sized scaffold design, its remarkable complex stability, and low toxicity; TSAG0101 should be considered as an innovative insulin-mimetic principle with promising properties and, therefore, could become a new lead compound for potential nonpeptide PTP1B inhibitors in antidiabetic drug research. In view of the present work, the inhibitory concentration (IC₅₀) and extended solution stability will be tested.

Keywords: inhibitors, PTP1B, computer assisted drug design (CADD), insulin, diabetes

Introduction
There are 2 clinical forms of diabetes mellitus. Type 1 (or juvenile) diabetes is primarily due to autoimmune-mediated destruction of pancreatic β-cell islets, resulting in an absolute insulin deficiency. Patients with type 1 diabetes depend on a daily exogenous insulin administration (IM) to prevent the development of ketoacidosis. Its frequency is low when compared to that of type 2 diabetes, which accounts for over 90% of all reported cases worldwide. Type 2 diabetes is characterized by insulin resistance (peripheral or extrapancreatic) and/or abnormal insulin secretion (pancreatic), either of which may predominate. At the beginning, type 2 patients do not depend on exogenous insulin uptake, but may require it for controlling blood glucose levels if this cannot be
achieved with diet alone or combined with oral hypoglycemic agents. Changes in living conditions, habits, and lifestyle over the last century have led not only to a dramatic increase in life span but also to the incidence of type 2 diabetes known as “diabesity” or “metabolic syndrome.” In conjunction with genetic susceptibility, particularly in certain ethnic groups, type 2 diabetes is caused by environmental and behavioral factors such as sedentary lifestyle, overly rich nutrition, and obesity. The prevention of diabetes and control of its micro- and macrovascular complications will require an integrated approach for the significant reduction in the huge premature morbidity and mortality it causes.

Current therapeutic approaches have largely been developed in the absence of defined molecular targets or even a solid understanding of disease pathogenesis. Within the recent past, our understanding of biochemical pathways related to the development of metabolic syndrome has expanded. Now, there is a steady growing range of molecular drug targets within these pathways. They are identified on the basis of predicted roles in modulating one or more key aspects of the pathogenesis of diabetes or metabolic syndrome. Several mechanistic categories for new therapeutic approaches can be considered. In a key position are approaches aimed at reducing excessive glucose production by the liver, besides mechanisms to augment glucose-stimulated insulin secretion, specific molecular targets in the insulin signaling pathway, and new approaches to obesity and altered lipid metabolism, which offer the prospect of net improvements in insulin action (or secretion).

The insulin signaling pathway starts with the binding of insulin to the extracellular α subunit of the transmembranal insulin receptor leading to a conformational change in the intracellular β subunit and promotion of the autophosphorylation at a number of tyrosine residues, Y + P = PY (Figure 1). Although the receptor protein tyrosine kinase is a positive regulator of the signal transduction, the protein tyrosine phosphatase (PTP) represents a negative one. The insulin receptor itself acts as a tyrosine kinase by transferring

**Figure 1** Schematic display of potential biomolecular targets of vanadium compounds within the human cell. The metabolic pathway of the insulin cascade is depicted. A double line symbolizes the cellular membrane, with the extracellular part above and the intracellular part below.

**Abbreviations:** Letter V, possible vanadium target; P/PY, tyrosine residue phosphorylated/nonphosphorylated; RPTK, receptor protein tyrosine kinase (positive regulator); PTP, protein tyrosine phosphatase (negative regulator); Y-prot, nonphosphorylated cytosolic protein; PY-prot, phosphorylated cytosolic protein; SRI-1, substrate 1 for the insulin receptor; Cyt-PTK, cytosolic protein tyrosine kinase.
phosphate to different receptor substrates, especially insulin receptor substrate 1, which in turn propagates the insulin signaling through phosphate transfer to cytoplasmatic proteins (Y-prot), and all the metabolic effects further downstream. In the process, insulin increases glucose transport in fat and muscle cells by stimulating the translocation of the transporter GLUT4 from intracellular sites to the plasma membrane and thereby promoting its exocytosis.6

Among the hitherto known PTPs, protein tyrosine phosphatase 1B (PTP1B) has received much attention due to its role as a negative regulator of insulin signaling.7,8 Clearly, a selective control of the biological function of PTP1B is a challenging task, and an inhibitor must not only efficiently bind to the specific target enzyme but also do so without impeding the catalytic behavior of closely related enzymes. The design of small molecule PTP1B inhibitors to treat type 2 diabetes has received considerable attention.9–15

Since the early discovery of the insulin-like activity of vanadate,16–18 VO₄³⁻, vanadium salts have kept their rank among the highest inhibitory activities against PTP9,15 although not in a selective manner. Other targets for monomeric vanadate or vanadyl are adenosine triphosphatases, adenyly cyclases, and calcium channels,19 and F-actin in the case of decavanadate (V₉⁻).20 Nevertheless, the insulin-like activities of a number of vanadium coordination compounds have been well documented.17,21–23 Some of their effects were found as enhancement of glucose uptake, biosynthesis of glycogen, as well as inhibition of gluconeogenesis or lipolysis.24,25 The molecular action mechanism of vanadate and the vanadium complexes has not yet been sufficiently established. However, after different studies, it is accepted now that vanadium targets may be protein phosphatases,26,18,27–30 instead of insulin hormone itself or insulin receptors GLUT2 and GLUT4 messengers.30 Recently, literature evidence appears in support of the hypothesis that active vanadium compounds may have intrinsic affinity to the PTP1B catalytic site.32–35

The insulin-like properties of vanadium have been demonstrated in a conclusive way based on in vitro experiments,36 in vivo assays in rats37,38 or mice,39 as well as in patients with diabetes.40 It is noteworthy to state that as yet all clinical studies have been carried out successfully using inorganic salts of vanadium, albeit it is beyond doubt that the true potential lies in the use of organic vanadium complexes, judging from the higher activity and the lower toxicity rates.41–43 In addition, vanadium insulin-mimetic effects are superior to other heavy metals (Cr, Zn, and Cd),44,45 since vanadium research seeks to strengthen therapeutic benefits over toxicities.46,47 Especially vanadium seems not to present negative accumulation effects.48 Our present study also aims at the ongoing discussion on the prodrug role of vanadium coordination compounds (stability against ubiquitous citrate).46 Different research teams have developed new organic compounds of vanadium to improve the drug properties. In the present work, due to the reported identification of a biomolecular target we could devise a so-called de novo design procedure. In a previous work,35 we demonstrated that vanadium compounds stated in the literature as the most active antidiabetics are also potential PTP1B inhibitors.35 Particularly, in the case of bis(maltolate) oxo-vanadium(IV) (BMOV) and ammonium bis(picolinate) oxo-vanadium(V), we determined the active conformations during simulated docking into the target enzyme (PTP1B).35,40

In the present work, we report the design, synthesis, bioassays, and toxicity tests for a new organic vanadium compound (TSAG0101).

Methods

De novo design

Vanadium complexes were designed by a chimeric procedure of combinatorial chemistry to obtain organic oxo-vanadium complexes of type VO₂L where V is the central vanadium atom and L stands for ligand. The former imitates the geometry of a phosphate anion, phosphatomimetic group,46 whereas the latter is composed of unrelated organic rests (strong chelating groups). To this end, pharmacologically and chemically known molecular fragments (A, B, and Q in Figure 2) were combined to build an imaginary compound using Chem3D of the ChemOffice 5.0 tool box.50 Each building block (fragment) follows a specific structural pattern and function:

1. Quelate fragment (Q): coordinates the dioxovanadate ion, VO₄³⁻ and interacts with the Cys215 from the PTP1B. Furthermore, these molecular fragments have aromatic interaction with residues Phe182 and Tyr46.
2. Basic fragment (B): interacts with the acid residue Asp181, at the center of the PTP1B cavity.
3. Acidic fragment (A): allows the molecular recognition of the substrate by the external PTP1B residues Arg45 and Arg47.

Geometry optimization of designed complexes

Density functional theory (DFT) with B3LYP hybrid exchange – correlation functional is a well-accepted standard procedure in computing of the equilibrium geometry. Especially, DFT/B3LYP is used for molecular geometry optimization of ligands. The basis set for all atoms is
6–31 + G(d,p). A frequency computation is carried out using the optimized structures to provide a complete description of the molecular motions in normal mode. The absence of the imaginary frequencies after diagonalization of Hessian matrix confirmed that the optimized structure is the real minima on the ground state hyperdimensional surface. By means of visual inspection using the Gaussview program, the modes can be assigned to the irreducible representations of the point groups. All calculations have been done using Gaussian03 program suite,51 and Gaussview V3.0952 has been used for visualizing the conformers.

Modeling of the interaction PTP1B (receptor) – vanadium complexes (ligand)
Prior to manual ligand docking at the active site of the crystal structure53 (PDB-code: 2HNP) of PTP1B,54 the Tripos force field in Sybyl55 was adapted for computing the steric and electrostatic energetics of ligand–receptor complex relaxations. In addition, modeling software packages MOE,56 Hyperchem,57 and ChemAxon58 were used during consecutive stages of the work and at different places (see Acknowledgments) with the methods reported elsewhere.35 In particular, chimeric candidates were fitted into the pharmacophore model based on intuitive grounds (guessing conformational entropy effects, hydrophobic burial, π-stacking, etc). Particularly, sensitive aspects of ligand docking like reliability and model limitations as well as target flexibility were considered and taken from the expert literature.59–61

Synthesis of VO$_2$L complexes
The synthesis of VO$_2$L complexes was accomplished with the triethyl ester of vanadic acid, VO(OEt)$_3$. For its in situ preparation, a procedure was adapted from literature.62 Finely grounded V$_2$O$_5$(s) was refluxed in absolute ethanol overnight, the ethanol was previously treated with molecular sieve. The resultant olive green-colored slurry was cooled to room temperature and then filtered through a tared fritted glass filter to yield a clear, pale yellow solution of VO(OEt)$_3$. The filtered

![Chelate fragments](image)

![Basic fragments](image)

![Acid fragments](image)

Figure 2 Molecular subunits used for the chimeric procedure. The design scheme allows the insertion of 2 or 3 fragments.
solid was dried by air flux, and its mass was determined every hour until constant weight. Yield of VO(OEt)$_3$ was calculated from the difference in the initial and recovered masses of V$_2$O$_5$, assuming that the recovered solid was unreacted V$_2$O$_5$. Previously prepared solution of VO(OEt)$_3$ (filtered eventually) was stirred at room temperature. The ligand was added very slowly (stoichiometry 1:1) and dissolved in the minimum of ethanol. After ligand addition, there was a color change in the solution from pale green-yellow to a bright clear yellow. The resulting reaction mixture was stirred at room temperature for 1 hour after the addition of the ligand. Volume was reduced by half or until the appearance of solid, using a rotary evaporator with vacuum pump. At this point, the solution was put aside for slow crystallization by evaporation at room temperature, until the product had precipitated completely. Reaction mixture was decanted and ethanol was added to the slurry to double the volume. Ethanol was previously treated with a molecular sieve. The solid was washed vigorously with the ethanol and then put aside for precipitation, after the complete precipitation the mixture was decanted, these washes were done until the supernatant was not colored and a final wash was performed with a mixture 80:20 ethanol:acetone. Solution was decanted and the slurry was dried in a vial under vacuum. Spectroscopy characterization was done by infrared (IR [KBr]), $^1$H and $^{13}$C nuclear magnetic resonance (NMR) in deuterated water.

**Solution stability of VO$_2$L complexes**

For the solution stability tests, 2 solutions were prepared: one is vanadium compound in a concentration of $2.5 \times 10^{-4}$ M, physiological pH 7.4 and the other one containing sodium citrate 1:1, which is a natural reducing and chelating agent for vanadium. The solutions were used for experiments of accumulation of spectra carried out for 27 hours.

**Pancreatic activity of VO$_2$L complexes**

Inbred, female Lewis rats (200 g) were purchased from Charles River (Sulzfeld, Germany). Islets were isolated by collagenase digestion$^{63}$ and purified by handpicking under the binocular. Batches of 5 freshly isolated islets were incubated in 1 mL of medium for 1 hour at 37°C. The incubation medium consisted of (mM) Na$^+$, 122; K$^+$, 4.7; Ca$^{2+}$, 2.5; Mg$^{2+}$, 1; Hapes, 10. The medium was supplemented with albumin (0.5%) and glucose. The pH was adjusted to 7.4 with NaOH. The test substance was dissolved in glucose-free incubation medium. Batches of 5 freshly isolated islets were incubated in 1 mL of incubation buffer for 1 hour at 37°C. After 1 hour of incubation, the samples were rapidly cooled on ice and an aliquot of medium was saved for insulin determination. The insulin content of each sample was analyzed in duplicate by enzyme-linked immnosorbent assay (Mercodia AB, Sweden) and the duplicate mean was entered as one observation. Values are means + standard deviation observed in 3 independent islet preparations.

**LD$_{50}$ test of VO$_2$L complexes**

The following lists the main facts of the lethal dose (LD$_{50}$) test in an order that follows the procedure:

**Test substances**

vanadium complex synthesized in this work; ammonium vanadate, NH$_4$VO$_3$, as reference.

**Method**

Oral Acute Toxicity Up-And-Down-Procedure, published by the Organization for Economic Cooperation and Development (OECD), in the document: “Guideline for the Testing of Chemicals, SECTION 4: Health Effects Test No. 425, Oral Acute Toxicity: Up-and-Down Procedure.”$^{64}$

**Software**

Oral Acute Toxicity Statistical Program (Guideline 425; AOT425StatPgm).$^{65}$

Animal model: 15 mice for substance, provided by the Bioterio “Claude Bernard,” BUAP.

**Administration**

intragastric, dose according to program, diluted in 2 cm$^3$ of solution of NaCl 0.3%.

**Procedure**

According to the OECD “Guideline for the Testing of Chemicals,”$^{65}$ with a preliminary value of 175 mg/kg and a factor of progression of dose of 3.2 for NH$_4$VO$_3$. In the case of the tested vanadium compound, the reference value of LD$_{50}$ was that of the compound BMOV, 220 mg/kg.$^{66}$ Test consists of the dosing of the animals, one at a time, in intervals of 48 hours. The first animal receives a dose a step behind from the reference value of LD$_{50}$. If the animal survives, the dose for the following animal is increased by an adaptor factor of dose progression (default, 3.2 times). Dosification tree is shown in Scheme 1. Each animal should be observed carefully for 48 hours, before making a decision about its short-term survival. All animals are kept under observation for 14 days in total, to establish their long-term survival. The survival data in the short run for each animal are registered in the software AOT425StatPgm, and the program assesses the next dose until the program recognizes
of the 3 preestablished situations to stop the calculation loop. Once the dose assessment has been stalled, the results of long-term test data (14 days) are registered in the program. The animals were killed to end their suffering by humanitarian means before the end of the observation period, and were counted as dead. The LD50 values are calculated according to the statistical method of maximum probability.67,68

Results and discussion

Computer assisted drug design

In the first stage of the drug design study, the modeller of the group (TS) previously devised a pharmacophore model based on PTP1B inhibitors9–15 in collaboration and documented in a graduate thesis.49 Then, few suitable vanadium complexes (ligands) were created for the chimeric procedure described earlier. The geometries were optimized by Gaussian 03. A docking procedure inside the cavity was performed to accommodate the ligand in the best position. A criterion was established to look for the best binders and docked positions inside the active site: during manual docking, all those chimeric combinations with large repulsion due to steric hindrance were discarded. From the literature, certain experimental findings were taken into account to improve the final pharmacophore models: planar sandwich or face-to-face parallel-stacked geometry under an attractive charge-transfer interaction between aromatic systems showing electron-deficiency and electron-rich areas, with an energy gain of 1.5 kcal/mol at a distance between ring centers 5 nm.69 Similar observations were made by Gung et al70: ΔH of −2 kcal/mol and a ΔS of −3 kcal/mol. Especially, π-stacking with edge-to-face (T-shaped), also OH–π interactions, and Coulombic enzyme–substrate interactions are reported by Meyer et al.71 An empirical study observed that the aromatic side chains of amino acids prefer an off-centered parallel alignment in proteins (parallel displaced π-stacking).72 Moreover, calculations show that organic cationic compounds interact with π bonds very strongly (10–22 kcal/mol), and are even more stable than ion-pair interactions, like salt bridges between tetra-alkylammonium ions and anionic residues in aqueous solution. This is an important finding for molecular recognition by cation–π interactions.73

As a final result, a small-sized nonsubstituted vanadium compound, TSAG0101, constitutes a potential lead compound to build a novel series of insulin-mimetic drug candidates. Figure 3 displays the receptor–ligand complexes for the chimeric

![Diagram](image-url)
new insulin-mimetic vanadium compound to inhibit PTP1B was obtained. The product was a powder stable in air. The yield was of 65% with regard to vanadium. IR spectrum (KBr; Figure 4) showed the following bands: $\nu$/cm$^{-1}$ 3,570 (NH), 1,627 (C=O, co-ordinated), 1,417 (C–N), 970/842 (O=V=O), 727 $\delta$. (pyridine ring).

The successful complex formation of TSAG0101 was proven in the IR spectrum for the displacement of the carbonyl band from its original position in 1,664 cm$^{-1}$, up to 1,627 cm$^{-1}$ (Figure 5). Formation of the complex is evident from 2 bands corresponding to the group of dioxovanadate, O=V=O, in 970 and 842 cm$^{-1}$. The $^1$H NMR spectrum (Figure 5) reflects a group of 4 broad bands from 7.6 to 8.2 ppm due to the effect of the vanadium that has a quadrupolar nuclear magnetic moment and NH$_2$ shifted to 8.8 ppm. The solvent signal did not show the same broadening, given that no free vanadium ions are present in solution. $^{13}$C NMR: 5 bands between 122 and 151 ppm and carbonyl C shifted to 180 ppm (not shown).

The data discussed above agree with the formula [V$^\text{V}$O$_2$(OH)(picolinamide)] and the structure is shown in Figure 5.

**Solution stability of TSAG0101**

In the next step, the lead candidate TSAG0101 was synthesized and a product with a greenish yellow color was obtained. The product was a powder stable in air. The yield was of 65% with regard to vanadium. IR spectrum (KBr; Figure 4) showed the following bands: $\nu$/cm$^{-1}$ 3,570 (NH), 1,627 (C=O, co-ordinated), 1,417 (C–N), 970/842 (O=V=O), 727 $\delta$. (pyridine ring).

The successful complex formation of TSAG0101 was proven in the IR spectrum for the displacement of the carbonyl band from its original position in 1,664 cm$^{-1}$, up to 1,627 cm$^{-1}$ (Figure 5). Formation of the complex is evident from 2 bands corresponding to the group of dioxovanadate, O=V=O, in 970 and 842 cm$^{-1}$. The $^1$H NMR spectrum (Figure 5) reflects a group of 4 broad bands from 7.6 to 8.2 ppm due to the effect of the vanadium that has a quadrupolar nuclear magnetic moment and NH$_2$ shifted to 8.8 ppm. The solvent signal did not show the same broadening, given that no free vanadium ions are present in solution. $^{13}$C NMR: 5 bands between 122 and 151 ppm and carbonyl C shifted to 180 ppm (not shown).

The data discussed above agree with the formula [V$^\text{V}$O$_2$(OH)(picolinamide)] and the structure is shown in Figure 5.
Complexes with vanadium in oxidation state +5 display a band in the UV region from a charge transfer from ligand to metal, whereas those complexes with vanadium in oxidation state +4 possess 3 bands in the visible region. Cumulative spectra for TSAG0101 in aqueous solution with and without sodium citrate are shown in Figure 6. In the first case (Figure 6a), the spectrum changed very slowly with time, the charge transfer band near 400 nm fade away, and a new band appears in the visible region, possibly due to a change in oxidation state of the vanadium ion from +5 to +4. The spectrum for the solution with citrate behaved in the same way (Figure 6b), indicating that citrate did not form a new compound. Citrate is a very competitive reducer for metal ions; therefore, the experimental compound TSAG0101 is stable with respect to the exchange of ligands but it slowly reduces the oxidation state of vanadium from +5 to +4. The band observed at 400 nm also could be related with the presence of decavanadate. Nevertheless, this last species is not the most stable form of free vanadium at neutral pH and it has to be introduced from a stock solution to be present at low concentration.

Pancreatic activity
Rat islets responded with a 20-fold increase in insulin secretion to a change from substimulatory to stimulatory glucose concentrations. No effects of the test substance on basal- or glucose-induced insulin release were observed. There was a tendency to inhibit glucose-induced insulin secretion at the highest concentrations of test substance, this effect was, however, not significant. (Note: further samples with 16.7 mM glucose are available but could not be analyzed in this work due to inappropriate dilution preparations.) The data also indicate an inhibition at the highest concentration because the secretion data with a 100 µM test substance are in the range of detection, whereas all other values are still above that range (Table 1).

Glucose-induced insulin secretion in static incubation is a standard test to determine the metabolic activity of isolated islets. The 20-fold increase of glucose-induced insulin secretion demonstrates that the examined preparations consisted of very active islets. The high secretory activity in the presence of 11 mM glucose is a sensitive measure to detect a possible influence of the test substance on β-cell metabolism. No alteration of basal- or glucose-induced insulin secretion was observed excluding a direct effect of the test substance on β cells and, therefore, the observed blood glucose lowering effect in rats should be an extrapancreatic activity.

LD₅₀ test
Table 2 shows the experimental LD₅₀ values determined for both, NH₄VO₃ and TSAG0101 compounds, using the AOT425StatPgm software.

The reliability of the methodology used to obtain LD₅₀ values was confirmed with the value obtained for NH₄VO₃.

Table 1 Effect of the test substance TSAG0101 on glucose-induced insulin secretion. Batches of 5 freshly isolated rat islets were incubated for 1 hour with glucose and test substance as indicated. Insulin secretion was measured in ng/mL units. Values are means ± SD observed in 3 independent islet preparations.
since it is only slightly above the value reported by Ida et al.\(^7\) (55 mg/kg vs 10 mg/kg), which is probably due to experimental conditions and/or mathematical treatments; however, the value lies within the narrow range for all known vanadium inorganic salts (10–75 mg/kg) with the exception of sodium vanadate (300 mg/kg).

When directly compared, TSAG0101 (LD\(_{50}\) 412 mg/kg) is by far less toxic than caffeine (LD\(_{50}\) 192 mg/kg) and BMOV (220 mg/kg). Besides, being one of the most soluble vanadium complexes, this determines that its value of nominal LD\(_{50}\) becomes comparable with those of soluble substances (Table 3). In analogy, our observed LD\(_{50}\) value for TSAG0101 lies reasonably inside the range of LD\(_{50}\) values of other organic vanadium compounds that are classified as moderately toxic, according to the scales established in the literature.

**Conclusions**

Several vanadium compounds with hypoglycemic activity have already been patented.\(^7\)–\(^8\) In particular, an ethyl-derivative of BMOV entered clinical trials.\(^17\),\(^8\) In addition, vanadium appears as bio-conjugates and in nutritional supplements, as well as in cases of illegal doping. In drug research, its therapeutic performance is subjected to further scrutiny.\(^8\),\(^4\)

As a direct result of our chimerical de novo design, TSAG0101 is proposed as a new lead candidate for its structural simplicity and chemical derivation potential. Our in silico studies led theoretical insight into its pharmacophore pattern and molecular blocking action. The ligand was successfully docked into the phosphate binding site of its target, the intracellular PTP1B enzyme. In our in vivo and in vitro activity tests, our synthesized compound showed less toxicity. The complex was found to be sufficiently stable in presence of ubiquitous sodium citrate at the test concentration because no changes occurred within 24 hours. However, the prodrug function of the experimental compound TSAG0101 cannot be ruled out given the complex chemistry of vanadium compounds in aqueous solution. This finding could be interpreted against the hypothesis of prodrug function which cannot be ruled out for the more unstable organic vanadium compounds.\(^4\) With regard to the patented compounds,\(^7\)–\(^8\) an enhanced pharmacokinetic and dynamic drug profile of TSAG0101 can be expected; due to its experimental complex stability and theoretical binding specificity. In biological assays in rats, TSAG0101 showed insulin-like activity (insulin mimesis), also no pancreatic component could be observed, ie, its blood glucose lowering effect is of extrapancreatic nature. It is also less toxic than caffeine (LD\(_{50}\) 192 mg/kg) and BMOV (220 mg/kg). Because of the present work which extends the known literature on nonpeptidic insulin mimetics, more studies can be conducted in the future to assess the inhibitory concentration (IC\(_{50}\)) activities, as well as extended stability test in aqueous solutions under varying concentrations and temperatures by NMR and electron paramagnetic resonance spectroscopy.

**Table 2** Results of LD\(_{50}\) tests for NH\(_4\)VO\(_3\) and TSAG0101

| Test/substance  | NH\(_4\)VO\(_3\) (ammonium vanadate) | TSAG0101 |
|----------------|------------------------------------|----------|
| Preliminary estimate | 175 | 220 |
| LD\(_{50}\), mg/kg | 0.5 | 0.5 |
| Sigma estimate, mg/kg | 2000, 550, 175, 55, 2000, 700, 220, 70, 22, 7, 2.2, 0.7 |
| Recommended dose progression | 17.5, 5.5, 1.75 |
| Essay animal number | 8 |
| LD\(_{50}\) calculated, mg/kg | 55 | 412 |
| Confident interval to 95% probability, mg/kg | 35.02–155 | 220–700 |

**Table 3** Solubility data and LD\(_{50}\) values for some vanadium salts and compounds

| Vanadium compounds | Formula | Solubility in water g/L 20°C | LD\(_{50}\) mouse, mg/kg | References |
|--------------------|---------|------------------------------|------------------------|------------|
| Vanadium pentoxide; vanadium(V) oxide; divanadium pentoxide | V\(_2\)O\(_5\) | 8 | 23.4 | 76 |
| Ammonium vanadate, ammonium metavanadate; vanadic acid ammonical salt | NH\(_4\)VO\(_3\) | 58 | 10 | 76 |
| Sodium vanadate; sodium metavanadate | Na\(_2\)VO\(_3\) | Slightly soluble | 300 | 86 |
| Sodium orthovanadate; sodium tetraoxovanadate | Na\(_3\)VO\(_4\) | Soluble | 220 | 87 |
| BMOV; bis-maltolateoxovanadate | VO(maltol)\(_2\) | Soluble | 412 | This work |
| TSAG0101 | – | Soluble | 192 | 88 |
| Caffeine | NaCN | Soluble | 6.4 | 7 |

Drug Design, Development and Therapy 2010:4

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

239
We also expect the new compound will contribute to shed some light into the ongoing prodrug discussion either identifying or discarding the existence of active specie(s). In addition, side chain derivation is thought to improve the target selectivity of our nonsubstituted lead candidate which we make accessible for future research work.

Acknowledgments
At University of Tübingen, Germany: to Prof Dr Stefan Lauffer and Dr David Domeyer, for collaboration, numerous invitations, and bibliographic, hardware and software support during our visits (SYBYL, MOE); to Prof Dr Reiner Lammers, for in vitro inhibition and activity tests; to PhD Dr Nicolas Lambert, for the extra-pancreatic tests; to Prof Dr H.P.T. Ammon, for discussions. In Mexico: to VIEP-BAUP for projects MEBF-NAT10-G and SCJT-NAT10-I; to CONACyT, for the financial support of Project H38G01: “Desarrollo Teórico de Nuevos Fármacos Miméticos de Insulina Asistidos por Computadora”; and 2007/526392. Our gratitude is also extended to Chemical Computing Group with MOE (2004, 6) as well as ChemAxon for providing free academic modeling tools.

This article is dedicated to Prof Dr H.P.T. Ammon, Tübingen, Germany, on occasion of his birthday on 24.01.2011.

Disclosure
The authors report no conflicts of interest in this work.

References
1. World Health Organization. Diagnosis and classification of diabetes mellitus. Department of Noncommunicable Disease Surveillance, Geneva; 1999.
2. Astrup A, Finer N. Redefining type 2 diabetes: “diabetes” or “obesity dependent diabetes mellitus”. Obesity Rev. 2000;1:57–59.
3. World Health Organization. Diabetes Mellitus: Report of a WHO Study Group. Geneva; 1985.
4. Zimmert F, Alberti KGMM, Shaw J. Global and societal implication of the diabetes epidemic. Nature. 2001;414:782–787.
5. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 2001;414:821–827.
6. Saltiel AR, Khan CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806.
7. Cheng A, Dubé N, Gu F, Tremblay ML. Coordinated action of protein tyrosine phosphatase 1B gene. Science. 1999;283:1354–1358.
8. Elchelyb M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science. 1999;283:1354–1358.
9. Doman TN, McGovern SL, Witherbee BJ, et al. Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem. 2002;45:2213–2221.
10. Patankar SJ, Jurs PC. Classification of inhibitors of protein tyrosine phosphatase 1B using molecular structure based descriptors. J Chem Inf Comp Sci. 2003;43:885–899.
11. Shen K, Keng Y-F, Wu L, Guo X-L, Lawrence DS, Zhang Z-Y. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem. 2001;276(50):47311–47319.
12. Sun J-P, Fedorov AA, Lee S-Y, et al. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J Biol Chem. 2003;278(14):12406–12414.
13. Szczepankiewicz BG, Liu G, Hajduk PJ, et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc. 2003;125(14):4087–4096.
14. Wang H, Lim KL, Yeo SL, et al. Isolation of a novel protein tyrosine phosphatase inhibitor, 2-methyl-ferul enol, and its precursors from Streptomyces. J Nat Prod. 2000;63(12):1641–1646.
15. Groves MR, Yao Z-J, Roller PP, Burke TRJ, Barford D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochim. 1998;79(51):17773–17783.
16. Shechter Y, Karlish SJ. Insulin-like stimulation of glucose oxidation in rat adipocytes by vanadyl (IV) ions. Nature (Lond). 1980;284:556–558.
17. Thompson KH, Orvig C. Vanadium in diabetes: 100 years from phase 0 to phase I. J Inorg Biochem. 2006;100:1925–1935.
18. Xu, M., Glover NR, Tracey AS, Kinetics and molecular modeling studies of the inhibition of protein tyrosine phosphatases by N,N-dimethyldihydroxylamine complexes of vanadum(V). J Inorg Biochem. 1998;93:534–542.
19. Domingo JL. Vanadium: a review of the reproductive and developmental toxicity. Reprod Toxicol. 1996;10(3):175–182.
20. Ramos S, Rui O, Duarte RO, Moura JG, Aureliano M. Decavanadate interactions with actin: cysteine oxidation and vanadyl formation. Dalton Trans. 2009;7985–7994.
21. Thompson KH, Orvig C. Design of vanadium compounds as insulin enhancing agents. J Chem Soc, Dalton Trans. 2000;2885–2892.
22. Pereira MJ, Carvalho E, Eriksson JW, Crans DC, Aureliano M. Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes. J Inorg Biochem. 2009;103:1687–1692.
23. Nilsson J, Degerman E, Haukka M, et al. Bis- and tris(pyridyl)amine-oxidovanadium complexes: characteristics and insulin-mimetic potential. Dalton Trans. 2009;7902–7911.
24. Shechter Y, Eldberg G, Shisheva A, et al. In: Tracey AS, Crans DC, editors. Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications. Washington, DC: American Chemical Society; 1998;vol. 711:308–315.
25. Cazaronoli LH, Zanatta L, Jorge AP, et al. Follow-up studies on glycosylated flavonoids and their complexes with vanadium: their anti-hyperglycemic potential role in diabetes. Chem Biol Interact. 2006;163:177–191.
26. Huyer G, Liu S, Kelly J, et al. Mechanism of inhibition of protein tyrosine phosphatases by vanadate and pervanadate. Inorg Biochem. 1997;72(2):843–851.
27. Posner BI, Faure R, Burgess JW, et al. Peroxovanadium compounds. A new class of potent phospho-tyrosine phosphatase inhibitors which are insulin mimetics. J Biol Chem. 1994;269:4596–4604.
28. Crans DC, In: Tracey AS, Crans DC, editors. Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic Applications. Washington, DC: American Chemical Society; 1998; vol. 711:82–103.
29. Cunic C, Detich N, Ethier D, Tracey AS, Gresser MJ, Ramachandran CJ. Vanadate inhibition of protein tyrosine phosphatases in Jurkat cells: modulation by redox state. J Biol Inorg Chem. 1999;4:354–359.
30. Tracey AS. Hydroxamido vanadates: aqueous chemistry and function in protein tyrosine phosphatases and cell cultures. J Inorg Biochem. 2000;80:11–16.
31. Goldwasser I, Gefel D, Gershonov E, Fridkin M, Shechter Y. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem. 2000;80:21–25.
32. Li J, Guo SJ, Su H, Han LJ, Shi DY. Total synthesis of bis-(2,3-dibromo-4,5-dihydroxyphenyl)-methane as potent PTP1B inhibitor. Chin Chem Lett. 2008;19(11):1290–1292.

33. Li M, Ding W, Baruah B, Crans DC, Wang R. Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis[maltolato] oxovanadium(IV). J Inorg Biochem. 2008;102:1846–1853.

34. Seale AP, De Jesus LA, Kim S-Y, et al. Development of an automated protein-tyrosine phosphatase 1B inhibition assay and the screening of putative insulin-enhancing vanadium(IV) and (IV) compounds. Biotech Lett. 2005;27:221–225.

35. Scior JT, Mack H-G, Guevara-Garcia JA, Koch W. Antidiabetic bis-maltolato-oxovanadate(IV): conversion of inactive trans- to active cis-BMOV for possible binding to target PTP-1B. Drug Dev Devel Ther. 2008;2:221–231. ISSN: 1177–8881. Available from: http://www.dovepress.com/articles.php?article_id=2591&l=es&dfw=2XRX pTiGDXL1YVeV27174.

36. Kiersztan A, Jarzyna R. Inhibitory effect of vanadium compounds on glutamate dehydrogenase activity in mitochondria and hepatocytes isolated from rabbit liver. Pharmacol Toxicol. 1998;82(4):167–172.

37. Brichard SM, Okitolonda W, Henquin JC. Long term improvement of diabetes and hypertension in type 2 diabetic KKAy mice by bis(allixinato) vanadium when ingested with a tea decoction in streptozotocin-induced diabetic rats. Metab Clin Exp. 2006;55:263–270.

38. Adachi Y, Yoshikawa Y, Yoshida J, et al. Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAY mice by bis(allixinato) vanadate(IV) complex. Biochem Biophys Res Comm. 2006;345: 945–950.

39. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J Clin Endocrinol Metab. 1995;80:3311–3320.

40. Shechter Y, Goldwaer I. Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord Chem Rev. 2003;237:13–22.

41. Yamaguchi M, Wakasugi K, Saito R, et al. Syntheses of vanadyl and zinc(II) complexes of 1-hydroxy-4,5,6-substituted 2(1H)-pyrimidinones and their insulin–mimetic activities. J Inorg Biochem. 2006;100:260–269.

42. Zhang Y, Yang X-D, Wang K, Crans DC. The permeability and cytotoxicity of insulin-mimetic vanadium(III, IV, V)-dipicolinate complexes. J Inorg Biochem. 2006;100:80–87.

43. Kiersztan A, Winiarska K, Drozak J, et al. Differential effects of vanadium, tungsten and molybdenum on inhibition of glucose formation in renal tubules and hepatocytes of control and diabetic rabbits: beneficial action of melatonin and N-acetylcysteine. Mol Cell Biochem. 2004;261:9–21.

44. Thompson KH, Chiles J, Yuen VG, Tse J, McNeill JH, Orvig C. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal mctal complexes. J Inorg Biochem. 2000;98:683–690.

45. Sciorto JT, Guevara-Garcia JA, Bernard P, Do Q-T, Domney D, Lauffer S. Are vanadium compounds drugable? Structures and effects of anti-diabetic vanadium compounds: a critical review. Mini-Rev Med Chem. 2005;5:995–1008.

46. National Toxicology Program, National Institute of Environmental Health Sciences. Chemical information review document for oral exposure to tetravalent and pentavalent vanadium compounds. Supporting Nomination for Toxicological Evaluation by the National Toxicology Program. 2008. National Institutes of Health, U.S. Department of Health and Human Services. Research Triangle Park, NC. Available from: http://ntp.niehs.nih.gov/ntp/htdocs/Chem_Background/ExSumPdf/NIEHS_Vanadium_compounds_508.pdf. Accessed Oct 29, 2009.

47. Facchini DM, Yuen VG, Battell ML, McNeill JH, Grynpas MD. The effects of vanadium treatment on bone in diabetic and non-diabetic rats. Bone. 2006;38:368–377.

48. Cavato MN, Ory AJW, Abagyan RA. The challenge of considering receptor flexibility in ligand docking and virtual screening. Curr Computer-Aided Drug Design. 2005;1(4):423–440.

49. Mohan V, Gibbs AC, Cummings MD, Jaeger EP, DesJarlais RL. Docking: successes and challenges. Current Pharmaceutical Design. 2005;11(3):323–333.

50. Kirov S, Zachwieja Z, Filipek B, Zygmunt M, Grybos R. Effect of vanadium compounds on nondiabetic and streptozotocin-diabetic rats. Arch Pharm Med Chem. 2001;334:388–392.

51. SAS Institute Inc. SAS/STAT User’s Guide. Version 6, Cary, NC, USA; 1990.

52. BMDP Statistics Software, Inc. BMDP Statistical Software Manual. Dixon WJ, Chief editor. Berkeley, CA, USA: University of California Press; 1990.
74. Crans DC, Yang L. Aqueous chemistry of ammonium (dipicolinato) oxovanadate(V): the first organic vanadium(V) insulin-mimetic compound. *Inorg Chem*. 2000;39:4409–4416.
75. Caravan P, Gelmini L. Reaction chemistry of BMOV, bis(maltolato) oxovanadium(IV) – a potent insulin mimetic agent. *J Am Chem Soc*. 1995;117:12759–12770.
76. Ida M, Imai K, Hashimoto S, Kawashima H. Pervanadate stimulation of wortmannin-sensitive and -resistant 2-deoxyglucose transport in adipocytes. *Biochem Pharmacol*. 1996;51:1061–1067.
77. Posner BI. *Ear Pat Appl*. 1988;264–278.
78. Orvig C, McNeill JH. US Patent. 6,287,586. 2001.
79. Orvig C, McNeill JH, Melchior M. US Patent. 6,268,357. 2001.
80. Makamoto K, Shintaro I, Hidehiro Y, Hiroshi S. *Japan Patent*. 1990;2292217A2.
81. Olarte AZ, Carpene C, Delmas GE-T, et al. *PCT Int Appl*. 2002;WO 02/38152.
82. Thompson KH, Lichter J, LeBel C, Scaife MC, McNeill JH, Orvig C. Vanadium treatment of type 2 diabetes: a view to the future. *J Inorg Biochem*. 2009;103:554–558.
83. Mukherjee R, Donnay EG, Radomski MA, et al. Vanadium–vitamin B12 bioconjugates as potential therapeutics for treating diabetes. *Chem Commun*. 2008;3783–3785.
84. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. *QJM*. 2008;101:351–358.
85. Lu B, Ennis D, Lai R, Bogdanovic E. Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). *J Biol Chem*. 2001;276:35589–35598.
86. Bjorge JD, Pang A, Fujita DJ. Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines. *J Biol Chem*. 2000;275:41439–41446.
87. Fantus IG, George R, Tang S, Chong P, Poznansky MJ. The insulin-mimetic agent vanadate promotes receptor endocytosis and inhibits intracellular ligand-receptor degradation by a mechanism distinct from the lysosomotropic agents. *Diabetes*. 1996;45:1084–1093.
88. Stone RL, Dixon JE. Protein-tyrosine phosphatase. *J Biol Chem*. 1994;269:31323–31326.